Frontlight ResearchEarly access
WithdrawnNo phase
Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer
Key facts
- Who runs it
- Guangzhou Bio-gene Technology Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 11 Dec 2024
- Ended
- 2 Mar 2026
- Type of study
- Interventional
- Treatments tested
- CAR-T
- Record updated
- 28 May 2026
- Why it stopped
- Due to corporate strategic adjustment.
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Voluntarily participate in this trial, sign the informed consent form
- Advanced colorectal cancer patients who have either failed standard treatment, experienced intolerable toxicity, or are unsuitable or unwilling to undergo standard treatment, and voluntarily agree to receive the current treatment
- Be able to provide immunohistochemical (IHC) test results from the past 2 years, indicating positive expression of CDH17/GUCY2C targets in tumor tissues
- Have at least one extracranial, measurable/assessable lesion according to RECIST 1.1 criteria
- Have an ECOG (Eastern Cooperative Oncology Group) performance status score of 0-1 and an expected survival duration of at least 3 months
- Have recovered from the toxicity associated with previous treatments, with a CTCAE toxicity grade of less than 2
- Have no significant hematopoietic dysfunction and possess adequate organ function
- Be able to meet the research center's requirements for apheresis/peripheral blood collection upon successful screening, or have acceptable stored blood cell separation products available
Who cannot take part
- Patients who have undergone or are awaiting organ transplantation
- Individuals who have received live (attenuated) virus vaccines within four weeks prior to screening
- Individuals who have participated in other clinical trials involving drugs within the past 30 days
- Patients who have had or currently have other malignant tumors within the past five years
- History of clinically significant central nervous system disorders, either in the past or at screening
- History of severe allergies
- Patients with severe cardiac disease
- Patients with severe hepatic and renal dysfunction or disorders of consciousness
- Patients with active autoimmune or inflammatory diseases
- Patients with objective evidence of past or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonia, severe lung function impairment, etc
- Infections requiring intravenous antibiotic therapy for control or are uncontrollable
- Alcoholics or individuals with a history of substance abuse
- Patients who, based on the investigator's judgment and/or clinical standards, have contraindications to any study procedures or present other medical conditions that may pose unacceptable risks
- Individuals who have received cytotoxic drugs or other interventions, assessed by the investigator as potentially impacting lymphocyte expansion, within 14 days or at least five half-lives (whichever is shorter) prior to blood collection for CAR-T preparation
- Presence of brain metastasis
- Imaging indicating tumor invasion of major blood vessels or indistinct borders with blood vessels
- Presence of other viremias
- Pregnant or lactating women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a single-arm, single-center investigator-initiated trial (IIT) designed to evaluate the safety and preliminary efficacy of CDH17/GUCY2C CAR-T cell therapy in patients with advanced colorectal cancer, as well as to assess its pharmacodynamic (PD) and pharmacokinetic (PK) profiles.
The group in the trial
- CAR-TTreatment being tested
The dosage range of 1.0 × 10\^6/kg (± 20%) to 5.0 × 10\^6/kg (± 20%) of CAR-T cells, administered either intravenously or intratumorally.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Study Evaluating the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer
- Record updated
- 28 May 2026